EYECARE Harrow Partners With Asembia to Enhance ECP and Patient Experience By Staff Monday, November 11, 2024 12:21 AM NASHVILLE, Tenn.—Harrow (Nasdaq: HROW), a North American eyecare pharmaceutical company, has announced the nationwide launch of a new digital patient access solution in collaboration with Asembia, a provider of specialty pharmacy and patient support hub services. This multi-year exclusive partnership is designed to expand access to Harrow’s ophthalmic branded products, including Flarex, Ilevro, Maxidex, Maxitrol, Natacyn, Nevanac, Tobradex ST, Verkazia, Vevye, Vigamox and Zerviate, by simplifying the prescribing process for eyecare professionals and improving both accessibility and affordability for patients, according to the announcement.ASPN Pharmacies is Asembia’s non-dispensing pharmacy, specializing in patient support services. ASPN collaborates with prescribers, patients, and payers to streamline the prescription process, ensuring rapid delivery through the patient’s preferred pharmacy and an exceptional patient experience, the company stated.“Our partnership with Asembia, leveraging ASPN, removes barriers to access and affordability for our branded eyecare products. By streamlining the entire patient journey—from prescription intake and benefits verification to prior authorization, co-pay support and patient assistance program eligibility—we’re making it easier for patients to access critical eyecare medications,” said Mark L. Baum, chairman and chief executive officer of Harrow. “ASPN’s advanced support centers enable providers to seamlessly submit prescriptions through their EHR/EMR systems, while ASPN handles the rest, including automating the refill process. Going forward, patients should be able to start their prescription therapies faster, at the lowest possible out-of-pocket cost, while also managing their refill process, ultimately driving greater compliance and better health outcomes.”Asembia chief executive officer Lawrence Irene, added, “We are thrilled to provide Harrow’s market leading ophthalmic formulary as our latest offering in the prescription ophthalmology category. From the outset, we recognized that Harrow’s innovative and high-quality products set the standard in eyecare. By partnering with Harrow, we’re able to enhance access to essential treatments, making them more accessible and affordable for patients, especially those who may have faced challenges through other channels. Our advanced patient and provider portal enhances this experience by providing complete transparency and support from prescription initiation to final delivery, empowering patients and providers every step of the way.”According to the announcement, health care providers can select ASPN Pharmacies directly from the dropdown menu in their EHR/EMR platforms or place orders directly through the ASPN provider portal. The ASPN provider portal enables physicians to order multiple Harrow branded products in a single order, simplifying the process.